123 related articles for article (PubMed ID: 15840846)
1. Cell division on-off switches sought as targets for cancer drugs.
Hampton T
JAMA; 2005 Apr; 293(15):1847. PubMed ID: 15840846
[No Abstract] [Full Text] [Related]
2. Farnesyl transferase inhibitors.
Li T; Sparano JA
Cancer Invest; 2008 Aug; 26(7):653-61. PubMed ID: 18665473
[No Abstract] [Full Text] [Related]
3. Mechanisms of drug inhibition of signalling molecules.
Sebolt-Leopold JS; English JM
Nature; 2006 May; 441(7092):457-62. PubMed ID: 16724058
[TBL] [Abstract][Full Text] [Related]
4. Kinase domain mutations in cancer: implications for small molecule drug design strategies.
Bikker JA; Brooijmans N; Wissner A; Mansour TS
J Med Chem; 2009 Mar; 52(6):1493-509. PubMed ID: 19239229
[No Abstract] [Full Text] [Related]
5. MKK3 as oncotarget.
Bossi G
Aging (Albany NY); 2016 Jan; 8(1):1-2. PubMed ID: 26805700
[No Abstract] [Full Text] [Related]
6. On or off target: mutations, models, and predictions.
Garraway LA; Hahn WC
Sci Transl Med; 2010 Jun; 2(35):35ps28. PubMed ID: 20538617
[TBL] [Abstract][Full Text] [Related]
7. Issues and progress with protein kinase inhibitors for cancer treatment.
Dancey J; Sausville EA
Nat Rev Drug Discov; 2003 Apr; 2(4):296-313. PubMed ID: 12669029
[TBL] [Abstract][Full Text] [Related]
8. Targeting cancer with small-molecular-weight kinase inhibitors.
Fabbro D; Cowan-Jacob SW; Möbitz H; Martiny-Baron G
Methods Mol Biol; 2012; 795():1-34. PubMed ID: 21960212
[TBL] [Abstract][Full Text] [Related]
9. Kinase inhibitor conjugates.
Harmsen S; Kok RJ
Curr Pharm Des; 2012; 18(20):2891-900. PubMed ID: 22571658
[TBL] [Abstract][Full Text] [Related]
10. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
Rowinsky EK
J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
[TBL] [Abstract][Full Text] [Related]
11. Redox-sensitive signaling factors as a novel molecular targets for cancer therapy.
Pennington JD; Wang TJ; Nguyen P; Sun L; Bisht K; Smart D; Gius D
Drug Resist Updat; 2005 Oct; 8(5):322-30. PubMed ID: 16230045
[TBL] [Abstract][Full Text] [Related]
12. Advancing the kinase field: new targets and second generation inhibitors.
Laufer S; Bajorath J
J Med Chem; 2015 Jan; 58(1):1. PubMed ID: 25490234
[No Abstract] [Full Text] [Related]
13. Kinase inhibitors and cytotoxic drug resistance.
Grant S; Dent P
Clin Cancer Res; 2004 Apr; 10(7):2205-7. PubMed ID: 15073093
[No Abstract] [Full Text] [Related]
14. Artificial signal transduction therapy: a futuristic approach to disease treatment.
Peri-Naor R; Motiei L; Margulies D
Future Med Chem; 2015; 7(16):2091-3. PubMed ID: 26510968
[No Abstract] [Full Text] [Related]
15. Resistance to epidermal growth factor receptor-targeted therapy.
Morgillo F; Lee HY
Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
[TBL] [Abstract][Full Text] [Related]
16. New insights into oncogene addiction found.
Garber K
J Natl Cancer Inst; 2007 Feb; 99(4):264-5, 269. PubMed ID: 17312299
[No Abstract] [Full Text] [Related]
17. Topoisomerase II inhibitors.
Toonen TR; Hande KR
Cancer Chemother Biol Response Modif; 2001; 19():129-47. PubMed ID: 11686011
[No Abstract] [Full Text] [Related]
18. Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review).
Withoff S; De Jong S; De Vries EG; Mulder NH
Anticancer Res; 1996; 16(4A):1867-80. PubMed ID: 8712715
[TBL] [Abstract][Full Text] [Related]
19. Sphingosine kinase/sphingosine 1-phosphate signaling in cancer therapeutics and drug resistance.
Selvam SP; Ogretmen B
Handb Exp Pharmacol; 2013; (216):3-27. PubMed ID: 23563649
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs.
Kohno M; Pouyssegur J
Prog Cell Cycle Res; 2003; 5():219-24. PubMed ID: 14593716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
